Analyzing...
Loading company...
Caplin Point Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Chennai, Tamil Nadu and currently employs 777 full-time employees. The firm is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). The company also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. The company has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,187 Cr revenue.
COGS 39.6%, employees 9.1%.
“Chile will be in the top five markets,”
“Nine months revenue is supposed to be generated revenue of $20.”
“revenue grew by 10.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 17.9%▲ | 10.3% |
| ROCE | 22.0%▲ | 13.7% |
| Net Margin | 27.9%▲ | 7.6% |
| EBITDA Margin | 38.1%▲ | 15.4% |
| Debt To Equity | 0.00x▼ | 0.15x |
| Rev Growth 3yr | 14.8%▲ | 10.0% |
| EPS Growth 3yr | 19.4%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,187 Cr +12.9% | ₹1,937 Cr +14.4% | ₹1,694 Cr +15.5% | ₹1,467 Cr +15.5% | ₹1,269 Cr +19.6% | ₹1,061 Cr +22.9% | ₹863 Cr +33.1% | ₹649 Cr |
| Other Income | ₹116 Cr +19.8% | ₹96 Cr +44.1% | ₹67 Cr +19.6% | ₹56 Cr +44.5% | ₹39 Cr +64.6% | ₹24 Cr -43.0% | ₹41 Cr +117.2% | ₹19 Cr |
| Total Income | ₹2,303 Cr +13.2% | ₹2,034 Cr +15.5% | ₹1,761 Cr +15.7% | ₹1,523 Cr +16.4% | ₹1,308 Cr +20.6% | ₹1,085 Cr +19.9% | ₹905 Cr +35.5% | ₹668 Cr |
| COGS | ₹866 Cr +12.3% | ₹771 Cr +6.4% | ₹724 Cr +9.2% | ₹663 Cr +19.0% | ₹558 Cr +18.2% | ₹472 Cr +14.2% | ₹413 Cr +43.1% | ₹289 Cr |
| ₹1,500 Cr +10.5% | ₹1,357 Cr +13.4% | ₹1,197 Cr +11.7% | ₹1,071 Cr +16.2% | ₹922 Cr +19.6% | ₹771 Cr +21.4% | ₹635 Cr +44.1% | ₹441 Cr | |
| Profit Before Tax | ₹803 Cr +18.6% | ₹677 Cr +19.9% | ₹564 Cr +25.1% | ₹451 Cr +17.0% | ₹386 Cr +23.0% | ₹314 Cr +16.4% | ₹269 Cr +18.8% | ₹227 Cr |
| ₹153 Cr +12.8% | ₹136 Cr +31.7% | ₹103 Cr +38.5% | ₹74 Cr -3.9% | ₹77 Cr +24.4% | ₹62 Cr +14.3% | ₹54 Cr +8.1% | ₹50 Cr | |
| Net Profit | ₹650 Cr +20.1% | ₹541 Cr +17.3% | ₹461 Cr +22.4% | ₹377 Cr +22.2% | ₹308 Cr +22.7% | ₹251 Cr +16.9% | ₹215 Cr +21.8% | ₹177 Cr |
| Profit (Owners) | ₹641 Cr +19.6% | ₹536 Cr +17.3% | ₹457 Cr +21.5% | ₹376 Cr +22.0% | ₹308 Cr +27.3% | ₹242 Cr +12.7% | ₹215 Cr +21.8% | ₹177 Cr |
| Minority Interest | ₹8 Cr +77.6% | ₹5 Cr +10.4% | ₹4 Cr +493.2% | ₹0.73 Cr | ₹0.00 Cr -100.0% | ₹9 Cr | ₹0.08 Cr ↑ Recovery | (₹0.01 Cr) |
| Other Comprehensive Income | ₹142 Cr +423.2% | ₹27 Cr +136.4% | ₹11 Cr -73.2% | ₹43 Cr +199.8% | ₹14 Cr ↑ Recovery | (₹7 Cr) ↓ Decline | ₹17 Cr ↑ Recovery | (₹0.26 Cr) |
| EPS | ₹84.36 | ₹70.56 | ₹60.19 | ₹49.57 | ₹40.70 | ₹32.03 | ₹28.42 | ₹23.35 |
| Diluted Shares | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr |
| Profit Or Loss Of Associates | ₹0.03 Cr ↑ Recovery | (₹0.01 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Caplin Point Laboratories Limited has informed the Exchange about Schedule of meet
Caplin Point Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Caplin Point Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Caplin Point Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 30-May-2026.
Caplin Point Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2026, declared Interim Dividend of Rs. 4 per equity share.
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Caplin Point Laboratories Limited has informed the Exchange about Schedule of meet
Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated May 05, 2026, titled "Receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA f...
Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated March 13, 2026, titled "Receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA...
Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the US...
Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the US...
Caplin Point Laboratories Limited has informed the Exchange about Transcript
Caplin Point Laboratories Limited has informed the Exchange about Link of Recording
Caplin Point Laboratories Limited has informed the Exchange about Investor Presentation
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.